← Back to Search

Virus Therapy

Viral Specific T-cells (VSTs) for Stem Cell Transplant

Phase 2

Waitlist Available

Led By Michael Grimley, MD

Research Sponsored by Children's Hospital Medical Center, Cincinnati

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days

Awards & highlights

Study Summary

This trial is investigating whether VSTs can help to prevent viral infections after stem cell transplant.

Eligible Conditions

Stem Cell Transplant
Viral Infections

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Acute Graft-Vs-Host Disease (aGVHD)

Number of Participants With Presence of a Toxicity

Secondary outcome measures

Number of Participants With Presence of a Viral Infection

Side effects data

From 2021 Phase 2 trial • 30 Patients • NCT03883906

GVHD, skin

GVHD, stomach

GVHD, sigmoid colon & rectum

100%

80%

60%

40%

20%

Study treatment Arm

Viral Specific T-cells (VSTs)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Viral Specific T-cells (VSTs)Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Viral Specific T-cells (VSTs)

2019

Completed Phase 2

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor

815 Previous Clinical Trials

6,531,566 Total Patients Enrolled

Hoxworth Blood CenterOTHER

6 Previous Clinical Trials

1,293 Total Patients Enrolled

Michael Grimley, MDPrincipal InvestigatorChildren's Hospital Medical Center, Cincinnati

1 Previous Clinical Trials

450 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent are Viral Specific T-cells (VSTs) considered safe for patients?

"There is minimal safety data to draw on, so Viral Specific T-cells (VSTs) were given a score of 2."

Answered by AI

Are there any remaining spots for participants in this trial?

"Based on the information accessible via clinicaltrials.gov, this trial does not currently have any open enrollment dates. It was initially posted in 16th March 2019 and had its most recent update on 5th May 2021; however 832 other trials are actively recruiting patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

2019. "Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03883906.